Massimo Falconi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2229145/publications.pdf

Version: 2024-02-01

586	49,157	2795	2027
papers	citations	94 h-index	205 g-index

595	595	595	29169
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The 2016 update of the International Study Group (ISGPS) definition and grading of postoperative pancreatic fistula: 11 Years After. Surgery, 2017, 161, 584-591.	1.0	2,655
2	A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer. New England Journal of Medicine, 2004, 350, 1200-1210.	13.9	2,442
3	Whole genomes redefine the mutational landscape of pancreatic cancer. Nature, 2015, 518, 495-501.	13.7	2,132
4	International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology, 2012, 12, 183-197.	0.5	2,043
5	Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science, 2018, 359, 926-930.	6.0	1,872
6	International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas. Pancreatology, 2006, 6, 17-32.	0.5	1,805
7	TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2006, 449, 395-401.	1.4	1,403
8	ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2016, 103, 153-171.	1.2	1,074
9	Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet, The, 2001, 358, 1576-1585.	6.3	1,019
10	European evidence-based guidelines on pancreatic cystic neoplasms. Gut, 2018, 67, 789-804.	6.1	878
11	MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical Behavior. Journal of Clinical Oncology, 2006, 24, 4677-4684.	0.8	752
12	Whole-genome landscape of pancreatic neuroendocrine tumours. Nature, 2017, 543, 65-71.	13.7	716
13	Main-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals of Surgery, 2004, 239, 678-687.	2.1	681
14	Pulmonary neuroendocrine (carcinoid) tumors: European Neuroendocrine Tumor Society expert consensus and recommendations for best practice for typical and atypical pulmonary carcinoids. Annals of Oncology, 2015, 26, 1604-1620.	0.6	514
15	Pancreatic Endocrine Tumors: Expression Profiling Evidences a Role for AKT-mTOR Pathway. Journal of Clinical Oncology, 2010, 28, 245-255.	0.8	497
16	ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors. Neuroendocrinology, 2012, 95, 120-134.	1.2	478
17	Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 10202-10207.	3.3	438
18	Branch-Duct Intraductal Papillary Mucinous Neoplasms: Observations in 145 Patients Who Underwent Resection. Gastroenterology, 2007, 133, 72-79.	0.6	422

#	Article	IF	Citations
19	TNM Staging of Neoplasms of the Endocrine Pancreas: Results From a Large International Cohort Study. Journal of the National Cancer Institute, 2012, 104, 764-777.	3.0	420
20	Mucinous Cystic Neoplasm of the Pancreas is Not an Aggressive Entity. Annals of Surgery, 2008, 247, 571-579.	2.1	407
21	European experts consensus statement on cystic tumours of the pancreas. Digestive and Liver Disease, 2013, 45, 703-711.	0.4	406
22	Reconstruction by Pancreaticojejunostomy Versus Pancreaticogastrostomy Following Pancreatectomy. Annals of Surgery, 2005, 242, 767-773.	2.1	398
23	Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Modern Pathology, 2010, 23, 824-833.	2.9	396
24	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. Gastroenterology, 2015, 149, 1501-1510.	0.6	376
25	Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocrine-Related Cancer, 2005, 12, 1083-1092.	1.6	360
26	Identification of a Novel Antibody Associated with Autoimmune Pancreatitis. New England Journal of Medicine, 2009, 361, 2135-2142.	13.9	327
27	Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor. Surgery, 2011, 150, 75-82.	1.0	306
28	Mucin-Producing Neoplasms of the Pancreas: An Analysis of Distinguishing Clinical and Epidemiologic Characteristics. Clinical Gastroenterology and Hepatology, 2010, 8, 213-219.e4.	2.4	289
29	Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary. Neuroendocrinology, 2008, 87, 47-62.	1.2	285
30	Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study. Journal of Clinical Oncology, 2010, 28, 1645-1651.	0.8	279
31	Pancreatic Fistula Rate after Pancreatic Resection. Digestive Surgery, 2004, 21, 54-59.	0.6	278
32	Serous cystic neoplasm of the pancreas: a multinational study of 2622 patients under the auspices of the International Association of Pancreatology and European Pancreatic Club (European Study Group) Tj ETQq0 0 0 rgBT /Overlock 10 T	6.1	274
33	Amylase Value in Drains After Pancreatic Resection as Predictive Factor of Postoperative Pancreatic Fistula. Annals of Surgery, 2007, 246, 281-287.	2.1	270
34	Duct-to-mucosa versus end-to-side pancreaticojejunostomy reconstruction after pancreaticoduodenectomy: results of a prospective randomized trial. Surgery, 2003, 134, 766-771.	1.0	264
35	Metastatic and Locally Advanced Pancreatic Endocrine Carcinomas: Analysis of Factors Associated With Disease Progression. Journal of Clinical Oncology, 2011, 29, 2372-2377.	0.8	261
36	Well-Differentiated Pancreatic Tumor/Carcinoma: Insulinoma. Neuroendocrinology, 2006, 84, 183-188.	1.2	248

#	Article	IF	Citations
37	Well-Differentiated Pancreatic Nonfunctioning Tumors/Carcinoma. Neuroendocrinology, 2006, 84, 196-211.	1.2	241
38	Management of Complications after Pancreaticoduodenectomy in a High Volume Centre: Results on 150 Consecutive Patients / with Invited Commentary. Digestive Surgery, 2001, 18, 453-458.	0.6	235
39	Branch-duct intraductal papillary mucinous neoplasms of the pancreas: to operate or not to operate?. Gut, 2007, 56, 1086-1090.	6.1	235
40	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours. Neuroendocrinology, 2017, 105, 255-265.	1.2	231
41	Autoimmune Pancreatitis: Differences Between the Focal and Diffuse Forms in 87 Patients. American Journal of Gastroenterology, 2009, 104, 2288-2294.	0.2	226
42	Alcohol and smoking as risk factors in chronic pancreatitis and pancreatic cancer. Digestive Diseases and Sciences, 1999, 44, 1303-1311.	1.1	225
43	Middle Pancreatectomy. Annals of Surgery, 2007, 246, 69-76.	2.1	222
44	Pancreatic insufficiency after different resections for benign tumours. British Journal of Surgery, 2007, 95, 85-91.	0.1	219
45	Observational Study of Natural History of Small Sporadic Nonfunctioning Pancreatic Neuroendocrine Tumors. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 4784-4789.	1.8	212
46	Minimally Invasive versus Open Distal Pancreatectomy for Ductal Adenocarcinoma (DIPLOMA). Annals of Surgery, 2019, 269, 10-17.	2.1	211
47	Efficacy of octreotide in the prevention of complications of elective pancreatic surgery. British Journal of Surgery, 2005, 81, 265-269.	0.1	203
48	Prognostic factors at diagnosis and value of WHO classification in a mono-institutional series of 180 non-functioning pancreatic endocrine tumours. Annals of Oncology, 2008, 19, 903-908.	0.6	200
49	Controlled clinical trial of pefloxacin versus imipenem in severe acute pancreatitis. Gastroenterology, 1998, 115, 1513-1517.	0.6	197
50	Management of 100 Consecutive Cases of Pancreatic Serous Cystadenoma: Wait for Symptoms and See at Imaging or Vice Versa?. World Journal of Surgery, 2003, 27, 319-323.	0.8	195
51	Genomeâ€wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLITâ€ROBO, ITGA2 and MET signaling. International Journal of Cancer, 2014, 135, 1110-1118.	2.3	192
52	Pancreatic tumours: molecular pathways implicated in ductal cancer are involved in ampullary but not in exocrine nonductal or endocrine tumorigenesis. British Journal of Cancer, 2001, 84, 253-262.	2.9	181
53	Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2â€“3 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 413-423.	3.7	180
54	Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis. Gut, 2017, 66, 495-506.	6.1	177

#	Article	IF	Citations
55	Incidence of Cancer in The Course of Chronic Pancreatitis. American Journal of Gastroenterology, 1999, 94, 1253-1260.	0.2	172
56	Enucleation of pancreatic neoplasms. British Journal of Surgery, 2007, 94, 1254-1259.	0.1	169
57	Clinicopathological features and treatment of intraductal papillary mucinous tumour of the pancreas. British Journal of Surgery, 2002, 88, 376-381.	0.1	163
58	Ki-67 grading of nonfunctioning pancreatic neuroendocrine tumors on histologic samples obtained by EUS-guided fine-needle tissue acquisition: a prospective study. Gastrointestinal Endoscopy, 2012, 76, 570-577.	0.5	158
59	Pattern and Clinical Predictors of Lymph Node Involvement in Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNETs). JAMA Surgery, 2013, 148, 932.	2.2	154
60	Parenchyma-Preserving Resections for Small Nonfunctioning Pancreatic Endocrine Tumors. Annals of Surgical Oncology, 2010, 17, 1621-1627.	0.7	153
61	Malignant pancreatic neuroendocrine tumour: Lymph node ratio and Ki67 are predictors of recurrence after curative resections. European Journal of Cancer, 2012, 48, 1608-1615.	1.3	149
62	(Ir)relevance of Metformin Treatment in Patients with Metastatic Pancreatic Cancer: An Open-Label, Randomized Phase II Trial. Clinical Cancer Research, 2016, 22, 1076-1085.	3.2	146
63	Resectable Pancreatic Cancer: Who Really Benefits From Resection?. Annals of Surgical Oncology, 2009, 16, 3316-3322.	0.7	143
64	Histomolecular Phenotypes and Outcome in Adenocarcinoma of the Ampulla of Vater. Journal of Clinical Oncology, 2013, 31, 1348-1356.	0.8	142
65	Italian consensus guidelines for chronic pancreatitis. Digestive and Liver Disease, 2010, 42, S381-S406.	0.4	140
66	Systematic review of active surveillance versus surgical management of asymptomatic small non-functioning pancreatic neuroendocrine neoplasms. British Journal of Surgery, 2016, 104, 34-41.	0.1	140
67	High recurrence rate after atypical resection for pancreatic metastases from renal cell carcinoma. British Journal of Surgery, 2003, 90, 555-559.	0.1	137
68	Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. American Journal of Gastroenterology, 2003, 98, 2435-2439.	0.2	137
69	Chronic pancreatitis: Report from a multicenter Italian survey (PanCroInfAISP) on 893 patients. Digestive and Liver Disease, 2009, 41, 311-317.	0.4	136
70	Systematic review and meta-analysis: Prevalence of incidentally detected pancreatic cystic lesions in asymptomatic individuals. Pancreatology, 2019, 19, 2-9.	0.5	136
71	MEN1 in pancreatic endocrine tumors: analysis of gene and protein status in 169 sporadic neoplasms reveals alterations in the vast majority of cases. Endocrine-Related Cancer, 2010, 17, 771-783.	1.6	135
72	Pancreatic cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v55-v58.	0.6	134

#	Article	IF	Citations
73	Neuroendocrine tumor disease: an evolving landscape. Endocrine-Related Cancer, 2012, 19, R163-R185.	1.6	133
74	A multimodality test to guide the management of patients with a pancreatic cyst. Science Translational Medicine, 2019, 11, .	5.8	129
75	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Follow-Up and Documentation. Neuroendocrinology, 2009, 90, 227-233.	1.2	128
76	Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. British Journal of Surgery, 2012, 99, 1480-1486.	0.1	128
77	Surgical Management of Insulinomas. Archives of Surgery, 2012, 147, 261.	2.3	126
78	Clinicopathological Features of Pancreatic Endocrine Tumors: A Prospective Multicenter Study in Italy of 297 Sporadic Cases. American Journal of Gastroenterology, 2010, 105, 1421-1429.	0.2	125
79	Rare Functioning Pancreatic Endocrine Tumors. Neuroendocrinology, 2006, 84, 189-195.	1.2	124
80	Behavior of antibiotics during human necrotizing pancreatitis. Antimicrobial Agents and Chemotherapy, 1994, 38, 830-836.	1.4	123
81	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology, 2017, 105, 245-254.	1.2	122
82	Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Annals of Oncology, 2006, 17, 461-466.	0.6	120
83	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. European Journal of Cancer, 2021, 146, 56-73.	1.3	120
84	Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumours: Well-Differentiated Tumour/Carcinoma of the Appendix and Goblet Cell Carcinoma. Neuroendocrinology, 2008, 87, 20-30.	1.2	119
85	Basophil Recruitment into Tumor-Draining Lymph Nodes Correlates with Th2 Inflammation and Reduced Survival in Pancreatic Cancer Patients. Cancer Research, 2016, 76, 1792-1803.	0.4	114
86	Total pancreatectomy: Indications, different timing, and perioperative and long-term outcomes. Surgery, 2011, 149, 79-86.	1.0	109
87	Italian consensus guidelines for the diagnostic work-up and follow-up of cystic pancreatic neoplasms. Digestive and Liver Disease, 2014, 46, 479-493.	0.4	108
88	Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. Journal of Endocrinological Investigation, 2004, 27, 6-11.	1.8	104
89	Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy?. European Journal of Surgical Oncology, 2016, 42, 1533-1539.	0.5	104
90	Role of Resection of the Primary Pancreatic Neuroendocrine Tumour Only in Patients with Unresectable Metastatic Liver Disease: A Systematic Review. Neuroendocrinology, 2011, 93, 223-229.	1.2	103

#	Article	IF	Citations
91	A New Scoring System to Predict Recurrent Disease in Grade 1 and 2 Nonfunctional Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2018, 267, 1148-1154.	2.1	101
92	Prospective multicentre survey on acute pancreatitis in Italy (ProInf-AISP): results on 1005 patients. Digestive and Liver Disease, 2004, 36, 205-211.	0.4	99
93	Prognosis of sporadic resected small (â‰¤2Âcm) nonfunctional pancreatic neuroendocrine tumors â€“ a multi-institutional study. Hpb, 2018, 20, 251-259.	0.1	99
94	Exocrine pancreatic insufficiency in adults: A shared position statement of the Italian association for the study of the pancreas. World Journal of Gastroenterology, 2013, 19, 7930.	1.4	98
95	Neuroendocrine pancreatic tumor. Abdominal Imaging, 2004, 29, 246-258.	2.0	96
96	â€œParaduodenalâ€•Pancreatitis: Results of Surgery on 58 Consecutives Patients from a Single Institution. World Journal of Surgery, 2009, 33, 2664-2669.	0.8	96
97	Molecular Characterization of Pancreatic Serous Microcystic Adenomas. American Journal of Pathology, 2001, 158, 317-321.	1.9	95
98	Role of disease-causing genes in sporadic pancreatic endocrine tumors:MEN1andVHL. Genes Chromosomes and Cancer, 2001, 32, 177-181.	1.5	95
99	Evidence-based Guidelines for the Management of Exocrine Pancreatic Insufficiency After Pancreatic Surgery. Annals of Surgery, 2016, 264, 949-958.	2.1	95
100	Incidental diagnosis as prognostic factor in different tumor stages of nonfunctioning pancreatic endocrine tumors. Surgery, 2014, 155, 145-153.	1.0	92
101	Nonfunctioning endocrine tumors of the pancreas: possibilities of spiral CT characterization. European Radiology, 2001, 11, 1175-1183.	2.3	91
102	Risk of death from acute pancreatitis. International Journal of Gastrointestinal Cancer, 1996, 19, 15-24.	0.4	87
103	Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocrine-Related Cancer, 2006, 13, 1213-1221.	1.6	87
104	Clinical and biological behavior of pancreatic solid pseudopapillary tumors: Report on 31 consecutive patients. Journal of Surgical Oncology, 2007, 95, 304-310.	0.8	87
105	Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Annals of Oncology, 2017, 28, 2786-2792.	0.6	87
106	A <scp>CD</scp>8Î±â^' Subset of <scp>CD</scp>4+<scp>SLAMF</scp>7+ Cytotoxic T Cells Is Expanded in Patients With IgG4â€Related Disease and Decreases Following Glucocorticoid Treatment. Arthritis and Rheumatology, 2018, 70, 1133-1143.	2.9	87
107	Contrast-enhanced ultrasonography better identifies pancreatic tumor vascularization than helical CT. Pancreatology, 2005, 5, 398-402.	0.5	86
108	Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy. American Journal of Surgery, 2012, 203, 132-139.	0.9	86

#	Article	IF	Citations
109	Faecal elastase-1 is an independent predictor of survival in advanced pancreatic cancer. Digestive and Liver Disease, 2012, 44, 945-951.	0.4	85
110	B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease. Journal of Allergy and Clinical Immunology, 2020, 145, 968-981.e14.	1.5	85
111	Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment. JAMA Oncology, 2020, 6, 1733.	3.4	85
112	Review of the clinical, histological, and molecular aspects of pancreatic endocrine neoplasms. Journal of Surgical Oncology, 2002, 81, 45-53.	0.8	84
113	Contrast-Enhanced Sonography of Nonfunctioning Pancreatic Neuroendocrine Tumors. American Journal of Roentgenology, 2009, 192, 424-430.	1.0	84
114	Partial Pancreaticoduodenectomy Can Provide Cure for Duodenal Gastrinoma Associated With Multiple Endocrine Neoplasia Type 1. Annals of Surgery, 2013, 257, 308-314.	2.1	84
115	Real-World Study of Everolimus in Advanced Progressive Neuroendocrine Tumors. Oncologist, 2014, 19, 966-974.	1.9	84
116	Comparison of Contrast-Enhanced Sonography and MRI in Displaying Anatomic Features of Cystic Pancreatic Masses. American Journal of Roentgenology, 2007, 189, 1435-1442.	1.0	83
117	A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. Endocrine Connections, 2016, 5, 174-187.	0.8	83
118	Prognostic Relevance of Lymph Node Ratio and Number of Resected Nodes after Curative Resection of Ampulla of Vater Carcinoma. Annals of Surgical Oncology, 2008, 15, 3178-3186.	0.7	82
119	Recurrence of Pancreatic Neuroendocrine Tumors and Survival Predicted by Ki67. Annals of Surgical Oncology, 2018, 25, 2467-2474.	0.7	82
120	International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Pancreatology, 2016, 16, 14-27.	0.5	81
121	Effectiveness of gabexate mesilate in acute pancreatitis. Digestive Diseases and Sciences, 1995, 40, 734-738.	1.1	80
122	Long-Term Follow-up of Patients with Chronic Pancreatitis in Italy. Scandinavian Journal of Gastroenterology, 1998, 33, 880-889.	0.6	79
123	Increased rate of clinically relevant pancreatic fistula after deep enucleation of small pancreatic tumors. Langenbeck's Archives of Surgery, 2014, 399, 315-321.	0.8	78
124	Risk of pancreatic malignancy and mortality in branch-duct IPMNs undergoing surveillance: A systematic review and meta-analysis. Digestive and Liver Disease, 2016, 48, 473-479.	0.4	78
125	Competitive Testing of the WHO 2010 versus the WHO 2017 Grading of Pancreatic Neuroendocrine Neoplasms: Data from a Large International Cohort Study. Neuroendocrinology, 2018, 107, 375-386.	1.2	78
126	Endocrine Neoplasms of the Pancreas: Pathologic and Genetic Features. Archives of Pathology and Laboratory Medicine, 2009, 133, 350-364.	1.2	78

#	Article	IF	Citations
127	Laparoscopic rectal resection for severe endometriosis of the mid and low rectum: technique and operative results. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 1035-1040.	1.3	76
128	A systematic review on robotic pancreaticoduodenectomy. Surgical Oncology, 2013, 22, 238-246.	0.8	76
129	Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. Digestive and Liver Disease, 2009, 41, 49-55.	0.4	73
130	Surgical Resection Does Not Improve Survival in Patients with Renal Metastases to the Pancreas in the Era of Tyrosine Kinase Inhibitors. Annals of Surgical Oncology, 2015, 22, 2094-2100.	0.7	72
131	CT-derived radiomic features to discriminate histologic characteristics of pancreatic neuroendocrine tumors. Radiologia Medica, 2021, 126, 745-760.	4.7	72
132	Smoking Cessation at the Clinical Onset of Chronic Pancreatitis and Risk of Pancreatic Calcifications. Pancreas, 2007, 35, 320-326.	0.5	71
133	Pancreatic Cystic Endocrine Tumors: A Different Morphological Entity Associated with a Less Aggressive Behavior. Neuroendocrinology, 2010, 92, 246-251.	1.2	71
134	Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: Possible indications for a multimodal approach. Surgery, 2014, 155, 607-614.	1.0	71
135	Long-Term Outcomes of Surgical Management of Pancreatic Neuroendocrine Tumors with Synchronous Liver Metastases. Neuroendocrinology, 2015, 102, 68-76.	1.2	71
136	Pancreatic endocrine tumours: evidence for a tumour suppressor pathogenesis and for a tumour suppressor gene on chromosome 17p. , 1998, 186, 41-50.		70
137	Development of a disease-specific quality of life questionnaire module for patients with gastrointestinal neuroendocrine tumours. European Journal of Cancer, 2006, 42, 477-484.	1.3	69
138	Invasive Intraductal Papillary Mucinous Carcinomas of the Pancreas. Annals of Surgery, 2010, 251, 477-482.	2.1	69
139	Parenchymaâ€sparing resections for pancreatic neoplasms. Journal of Hepato-Biliary-Pancreatic Sciences, 2010, 17, 782-787.	1.4	67
140	Systematic review and meta-analysis of metal versus plastic stents for preoperative biliary drainage in resectable periampullary or pancreatic head tumors. European Journal of Surgical Oncology, 2016, 42, 1278-1285.	0.5	67
141	Active Surveillance Beyond 5 Years Is Required for Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms Undergoing Non-Operative Management. American Journal of Gastroenterology, 2017, 112, 1153-1161.	0.2	66
142	Anastomotic leakage in pancreatic surgery. Hpb, 2007, 9, 8-15.	0.1	65
143	ENETS Consensus Guidelines for the Management of Bone and Lung Metastases from Neuroendocrine Tumors. Neuroendocrinology, 2010, 91, 341-350.	1.2	65
144	Methylation-associated down-regulation of RASSF1A and up-regulation of RASSF1Cin pancreatic endocrine tumors. BMC Cancer, 2011, 11, 351.	1.1	65

#	Article	IF	Citations
145	Impact of lymphadenectomy on survival after surgery for sporadic gastrinoma. British Journal of Surgery, 2012, 99, 1234-1240.	0.1	65
146	Long-term outcomes and prognostic factors in neuroendocrine carcinomas of the pancreas: Morphology matters. Surgery, 2016, 159, 862-871.	1.0	65
147	Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms. Surgery, 2018, 163, 761-767.	1.0	65
148	Multiple Endocrine Neoplasia Type 1 and the Pancreas: Diagnosis and Treatment of Functioning and Non-Functioning Pancreatic and Duodenal Neuroendocrine Neoplasia within the MEN1 Syndrome â€“ An International Consensus Statement. Neuroendocrinology, 2021, 111, 609-630.	1.2	63
149	Quantitative measurement of 18F-FDG PET/CT uptake reflects the expansion of circulating plasmablasts in IgG4-related disease. Rheumatology, 2017, 56, 2084-2092.	0.9	60
150	Management of ampullary neoplasms: A tailored approach between endoscopy and surgery. World Journal of Gastroenterology, 2015, 21, 7970.	1.4	59
151	Sex chromosome anomalies in pancreatic endocrine tumors. International Journal of Cancer, 2002, 98, 532-538.	2.3	58
152	Sunitinib, Pazopanib or Sorafenib for the Treatment of Patients with Late Relapsing Metastatic Renal Cell Carcinoma. Journal of Urology, 2015, 193, 41-47.	0.2	58
153	Resection of the Primary Tumor Followed by Peptide Receptor Radionuclide Therapy as Upfront Strategy for the Treatment of G1â€“G2 Pancreatic Neuroendocrine Tumors with Unresectable Liver Metastases. Annals of Surgical Oncology, 2016, 23, 981-989.	0.7	58
154	Endovascular Repair of 40 Visceral Artery Aneurysms and Pseudoaneurysms with the Viabahn Stent-Graft: Technical Aspects, Clinical Outcome and Mid-Term Patency. CardioVascular and Interventional Radiology, 2018, 41, 385-397.	0.9	58
155	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors:Echocardiography. Neuroendocrinology, 2009, 90, 190-193.	1.2	57
156	Pancreatic endocrine tumours: mutational and immunohistochemical survey of protein kinases reveals alterations in targetable kinases in cancer cell lines and rare primaries. Annals of Oncology, 2012, 23, 127-134.	0.6	56
157	Postpancreatectomy Acute Pancreatitis (PPAP). Annals of Surgery, 2022, 275, 663-672.	2.1	56
158	Risk Factors for Disease Progression in Advanced Jejunoileal Neuroendocrine Tumors. Neuroendocrinology, 2012, 96, 32-40.	1.2	55
159	Multi-institutional Pooled Analysis on Adjuvant Chemoradiation in Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2014, 90, 911-917.	0.4	55
160	The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer. , 2019, 7, 45.		54
161	Sonography versus helical CT in identification and staging of pancreatic ductal adenocarcinoma. Journal of Clinical Ultrasound, 2003, 31, 175-182.	0.4	53
162	A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors. Annals of Surgery, 2019, 270, 422-433.	2.1	53

#	Article	IF	Citations
163	Risk Factors for Sporadic Pancreatic Endocrine Tumors. American Journal of Gastroenterology, 2009, 104, 3034-3041.	0.2	52
164	Pancreatoblastoma in Adults: A Review of the Literature. Pancreatology, 2009, 9, 73-80.	0.5	52
165	Early Postoperative Prediction of Clinically Relevant Pancreatic Fistula after Pancreaticoduodenectomy: usefulness of C-reactive Protein. Hpb, 2017, 19, 580-586.	0.1	52
166	Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. European Journal of Internal Medicine, 2020, 74, 92-98.	1.0	52
167	Somatostatin Receptor Subtypes 2 and 5 Are Associated with Better Survival in Well-Differentiated Endocrine Carcinomas. Neuroendocrinology, 2009, 89, 223-230.	1.2	51
168	Current status of robotic distal pancreatectomy: A systematic review. Surgical Oncology, 2013, 22, 201-207.	0.8	51
169	The Role of Combined 68Ga-DOTANOC and 18FDG PET/CT in the Management of Patients with Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2014, 100, 293-299.	1.2	51
170	Risk of misdiagnosis and overtreatment in patients with main pancreatic duct dilatation and suspected combined/main-duct intraductal papillary mucinous neoplasms. Surgery, 2016, 159, 1041-1049.	1.0	51
171	Pancreatic abscess and other pus-harboring collections related to pancreatitis: A review of 108 cases. World Journal of Surgery, 1990, 14, 505-511.	0.8	50
172	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 1197-1205.	3.3	50
173	Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial. The Lancet Gastroenterology and Hepatology, 2018, 3, 691-697.	3.7	50
174	A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin inÂlocally advanced or borderline resectable pancreatic adenocarcinoma. European Journal of Cancer, 2018, 102, 95-102.	1.3	50
175	Nerves and Pancreatic Cancer: New Insights into a Dangerous Relationship. Cancers, 2019, 11, 893.	1.7	50
176	The Evolution of Surgical Strategies for Pancreatic Neuroendocrine Tumors (Pan-NENs). Annals of Surgery, 2019, 269, 725-732.	2.1	50
177	Pancreatic Enzyme Replacement Therapy in Pancreatic Cancer. Cancers, 2020, 12, 275.	1.7	50
178	Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma. Annals of Surgery, 2022, 276, 378-385.	2.1	50
179	Gabexate mesilate vs aprotinin in human acute pancreatitis (GA.ME.P.A.). International Journal of Gastrointestinal Cancer, 1993, 14, 117-124.	0.4	49
180	Clinical and Patient-Reported Outcomes After Pancreatoduodenectomy for Different Diseases. Pancreas, 2011, 40, 938-945.	0.5	49

#	Article	IF	Citations
181	Active Surveillance versus Surgery of Nonfunctioning Pancreatic Neuroendocrine Neoplasms â‰¥2 cm in MEN1 Patients. Neuroendocrinology, 2016, 103, 779-786.	1.2	49
182	Pancreaticojejunostomy is comparable to pancreaticogastrostomy after pancreaticoduodenectomy: an updated meta-analysis of randomized controlled trials. Langenbeck's Archives of Surgery, 2016, 401, 427-437.	0.8	49
183	The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. European Journal of Surgical Oncology, 2018, 44, 778-783.	0.5	49
184	Defining Benchmark Outcomes for Pancreatoduodenectomy With Portomesenteric Venous Resection. Annals of Surgery, 2020, 272, 731-737.	2.1	49
185	Enhanced recovery pathways in pancreatic surgery: State of the art. World Journal of Gastroenterology, 2016, 22, 6456.	1.4	49
186	Duodenal duplication cyst causing severe pancreatitis: Imaging findings and pathological correlation. World Journal of Gastroenterology, 2006, 12, 1630.	1.4	48
187	Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidence. Cancer Treatment Reviews, 2019, 77, 1-10.	3.4	48
188	Management of the pancreatic transection plane after left (distal) pancreatectomy: Expert consensus guidelines by the International Study Group of Pancreatic Surgery (ISGPS). Surgery, 2020, 168, 72-84.	1.0	48
189	Resectable Pancreatic Adenocarcinoma: Is the Enhancement Pattern at Contrast-Enhanced Ultrasonography a Pre-Operative Prognostic Factor?. Ultrasound in Medicine and Biology, 2009, 35, 1929-1937.	0.7	47
190	Management of Locally Advanced Pancreatic Cancer. Annals of Surgery, 2021, 273, 1173-1181.	2.1	47
191	The value of standard serum tumor markers in differentiating mucinous from serous cystic tumors of the pancreas: CEA, Ca 19-9, Ca 125, Ca 15-3. Langenbeck's Archives of Surgery, 2002, 387, 281-285.	0.8	46
192	Intraductal Papillary Mucinous Neoplasms and Chronic Pancreatitis. Pancreatology, 2006, 6, 626-634.	0.5	46
193	Usefulness of Technetium-99m Hexamethylpropylene Amine Oxime-Labeled Leukocyte Scintigraphy to Detect Pancreatic Necrosis in Patients with Acute Pancreatitis. Pancreatology, 2007, 7, 459-469.	0.5	46
194	Advanced Digestive Neuroendocrine Tumors. Pancreas, 2014, 43, 212-218.	0.5	46
195	Autologous Islet Transplantation in Patients Requiring Pancreatectomy: A Broader Spectrum of Indications Beyond Chronic Pancreatitis. American Journal of Transplantation, 2016, 16, 1812-1826.	2.6	46
196	Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. European Journal of Surgical Oncology, 2017, 43, 372-379.	0.5	46
197	Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms. Neuroendocrinology, 2019, 108, 26-36.	1.2	46
198	Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. Rheumatology, 2020, 59, 2435-2442.	0.9	46

#	Article	IF	Citations
199	Contrast-Enhanced Ultrasonographic Detection of Small Pancreatic Insulinoma. Journal of Ultrasound in Medicine, 2003, 22, 413-417.	0.8	45
200	Minimally Invasive Necrosectomy Versus Conventional Surgery in the Treatment of Infected Pancreatic Necrosis. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2013, 23, 8-20.	0.4	45
201	Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review. Advances in Medical Sciences, 2016, 61, 147-153.	0.9	45
202	Update on gastroenteropancreatic neuroendocrine tumors. Digestive and Liver Disease, 2021, 53, 171-182.	0.4	45
203	Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. PLoS ONE, 2017, 12, e0179445.	1.1	45
204	Perfusion CT can predict tumoral grading of pancreatic adenocarcinoma. European Journal of Radiology, 2013, 82, 227-233.	1.2	44
205	Surgery with Radical Intent: Is There an Indication for G3 Neuroendocrine Neoplasms?. Annals of Surgical Oncology, 2020, 27, 1348-1355.	0.7	44
206	Pancreatic Tumors and Immature Immunosuppressive Myeloid Cells in Blood and Spleen: Role of Inhibitory Co-Stimulatory Molecules PDL1 and CTLA4. An In Vivo and In Vitro Study. PLoS ONE, 2013, 8, e54824.	1.1	44
207	Retroperitoneal and peritoneal drainage and lavage in the treatment of severe necrotizing pancreatitis. Surgery, Gynecology & Obstetrics, 1990, 170, 197-203.	0.6	44
208	Evaluation of an enhanced recovery protocol after pancreaticoduodenectomy in elderly patients. Hpb, 2016, 18, 153-158.	0.1	43
209	Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome. Oncologist, 2017, 22, 409-415.	1.9	42
210	Surgical Treatment of Pancreatic Metastases from Renal Cell Carcinomas. Digestive Surgery, 1998, 15, 241-246.	0.6	41
211	Long-term Results of Frey's Procedure for Chronic Pancreatitis: A Longitudinal Prospective Study on 40 Patients. Journal of Gastrointestinal Surgery, 2006, 10, 504-510.	0.9	41
212	Evaluation of a predictive model for pancreatic fistula based on amylase value in drains after pancreatic resection. American Journal of Surgery, 2014, 208, 634-639.	0.9	41
213	Endovascular Treatment of Visceral Artery Aneurysms and Pseudoaneurysms in 100 Patients: Covered Stenting vs Transcatheter Embolization. Journal of Endovascular Therapy, 2017, 24, 709-717.	0.8	41
214	Meta-analysis of mortality in patients with high-risk intraductal papillary mucinous neoplasms under observation. British Journal of Surgery, 2018, 105, 328-338.	0.1	41
215	Increase of circulating memory B cells after glucocorticoid-induced remission identifies patients at risk of IgG4-related disease relapse. Arthritis Research and Therapy, 2018, 20, 222.	1.6	41
216	Cancer of the ampulla of Vater: chromosome 17p allelic loss is associated with poor prognosis. Gut, 2000, 46, 842-848.	6.1	40

#	Article	IF	Citations
217	Splenic Artery Invasion in Pancreatic Adenocarcinoma of the Body and Tail: A Novel Prognostic Parameter for Patient Selection. Annals of Surgical Oncology, 2011, 18, 3608-3614.	0.7	40
218	Management of small asymptomatic nonfunctioning pancreatic neuroendocrine tumors: Limitations to apply guidelines into real life. Surgery, 2019, 166, 157-163.	1.0	40
219	Zalecenia ogÃ³lne dotyczÄ…ce postÄ™powania diagnostyczno-terapeutycznego w nowotworach neuroendokrynnych ukÅ‚adu pokarmowego (rekomendowane przez PolskÄ… SieÄ‡ GuzÃ³w) Tj ETQq1 1 0.784314 rgBT /Overlock 10	0.8	40
220	Presentation and Outcome of Pancreaticoduodenal Endocrine Tumors in Multiple Endocrine Neoplasia Type 1 Syndrome. Neuroendocrinology, 2011, 94, 58-65.	1.2	39
221	Long-Term Outcome after Laparoscopic Bowel Resections for Deep Infiltrating Endometriosis: A Single-Center Experience after 900 Cases. BioMed Research International, 2014, 2014, 1-5.	0.9	39
222	Clinical Usefulness of 18 Fâ€Fluorodeoxyglucose Positron Emission Tomography in the Diagnostic Algorithm of Advanced Enteroâ€Pancreatic Neuroendocrine Neoplasms. Oncologist, 2018, 23, 186-192.	1.9	39
223	Heterogeneity of Duodenal Neuroendocrine Tumors: An Italian Multi-center Experience. Annals of Surgical Oncology, 2018, 25, 3200-3206.	0.7	39
224	ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors. Neuroendocrinology, 2009, 90, 203-208.	1.2	38
225	Familial pancreatic cancer in Italy. Risk assessment, screening programs and clinical approach: A position paper from the Italian Registry. Digestive and Liver Disease, 2010, 42, 597-605.	0.4	38
226	Pain relapses in the first 10 years of chronic pancreatitis. American Journal of Surgery, 1996, 171, 565-569.	0.9	37
227	A single-institution experience with fistulojejunostomy for external pancreatic fistulas. American Journal of Surgery, 2000, 179, 203-206.	0.9	37
228	Extent of surgical resections for intraductal papillary mucinous neoplasms. World Journal of Gastrointestinal Surgery, 2010, 2, 347.	0.8	37
229	Low Expression of ARHI Is Associated with Shorter Progression-Free Survival in Pancreatic Endocrine Tumors. Neoplasia, 2007, 9, 181-IN2.	2.3	36
230	Imaging of neuroendocrine gastroenteropancreatic tumours. Radiologia Medica, 2010, 115, 1047-1064.	4.7	36
231	Surgical treatment of pancreatic endocrine tumours in Italy: results of a prospective multicentre study of 262 cases. Langenbeck's Archives of Surgery, 2011, 396, 313-321.	0.8	36
232	Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2016, 98, 309-324.	2.0	35
233	Intraductal papillary mucinous neoplasms of the pancreas with concurrent pancreatic and periampullary neoplasms. European Journal of Surgical Oncology, 2016, 42, 197-204.	0.5	35
234	Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry. American Journal of Gastroenterology, 2019, 114, 665-670.	0.2	35

#	Article	IF	Citations
235	Pancreatic cystic manifestations in von Hippel-Lindau disease. International Journal of Gastrointestinal Cancer, 1997, 22, 101-109.	0.4	34
236	Successful xenografting of cryopreserved primary pancreatic cancers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2001, 438, 154-158.	1.4	34
237	Role of Chemoembolization in Synchronous Liver Metastases from Pancreatic Endocrine Tumours. Digestive Surgery, 1999, 16, 32-38.	0.6	33
238	Implications of increased serum amylase after pancreaticoduodenectomy: toward a better definition of clinically relevant postoperative acute pancreatitis. Hpb, 2020, 22, 1645-1653.	0.1	33
239	Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) â‰¥2 cm: Study Protocol for a Prospective Observational Study. Frontiers in Medicine, 2020, 7, 598438.	1.2	33
240	Pancreatic metastasis from leiomyosarcoma of the broad ligament of the uterus. Lancet Oncology, The, 2006, 7, 94-95.	5.1	32
241	Surgical Treatment of Pancreatic Tumors in Childhood and Adolescence: Uncommon Neoplasms with Favorable Outcome. Pancreatology, 2011, 11, 383-389.	0.5	32
242	Systematic review and meta-analysis on laparoscopic pancreatic resections for neuroendocrine neoplasms (PNENs). Expert Review of Gastroenterology and Hepatology, 2017, 11, 65-73.	1.4	32
243	Three-Dimensional Primary Cell Culture: A Novel Preclinical Model for Pancreatic Neuroendocrine Tumors. Neuroendocrinology, 2021, 111, 273-287.	1.2	32
244	Carcinoid crisis induced by receptor radionuclide therapy with 90Y-DOTATOC in a case of liver metastases from bronchial neuroendocrine tumor (atypical carcinoid). Journal of Endocrinological Investigation, 2006, 29, 563-567.	1.8	31
245	Ampullary somatostatinomas and jejunal gastrointestinal stromal tumor in a patient with Von Recklinghausenâ€™s disease. World Journal of Gastroenterology, 2007, 13, 2761.	1.4	31
246	Right hemicolectomy plus pancreaticoduodenectomy vs partial duodenectomy in treatment of locally advanced right colon cancer invading pancreas and/or only duodenum. Surgical Oncology, 2014, 23, 92-98.	0.8	31
247	Selection criteria in resectable pancreatic cancer: A biological and morphological approach. World Journal of Gastroenterology, 2014, 20, 11210.	1.4	31
248	Impact of Neoadjuvant Therapy in Resected Pancreatic Ductal Adenocarcinoma of the Pancreatic Body orÂTail on Surgical and Oncological Outcome: A Propensity-ScoreÂMatched Multicenter Study. Annals of Surgical Oncology, 2020, 27, 1986-1996.	0.7	31
249	Understanding the Meaning of Recovery to Patients Undergoing Abdominal Surgery. JAMA Surgery, 2021, 156, 758-765.	2.2	31
250	Open Pancreaticogastrostomy After Pancreaticoduodenectomy: A Pilot Study. Journal of Gastrointestinal Surgery, 2006, 10, 1072-1080.	0.9	30
251	GEPâ€“NETS UPDATE: A review on surgery of gastro-entero-pancreatic neuroendocrine tumors. European Journal of Endocrinology, 2014, 171, R153-R162.	1.9	30
252	Management of neuroendocrine carcinomas of the pancreas (WHO G3): A tailored approach between proliferation and morphology. World Journal of Gastroenterology, 2016, 22, 9944.	1.4	30

#	Article	IF	Citations
253	Early Detection of Pancreatic Cancer following the Diagnosis of Chronic Pancreatitis. Digestion, 1999, 60, 554-561.	1.2	29
254	Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology study Section of the Italian Society of Gastroenterology (SIGE). Digestive and Liver Disease, 2001, 33, 217-221.	0.4	29
255	Outcome of Open Necrosectomy in Acute Pancreatitis. Pancreatology, 2003, 3, 128-132.	0.5	29
256	Ultrasonography of the pancreas. 7. Intraoperative imaging. Abdominal Imaging, 2007, 32, 200-206.	2.0	29
257	Todani Type II Congenital Bile Duct Cyst. Annals of Surgery, 2015, 262, 130-138.	2.1	29
258	Phase 1B trial of Nab-paclitaxel plus gemcitabine, capecitabine, and cisplatin (PAXG regimen) in patients with unresectable or borderline resectable pancreatic adenocarcinoma. British Journal of Cancer, 2016, 115, 290-296.	2.9	29
259	A Systematic review and meta-analysis on the role of palliative primary resection for pancreatic neuroendocrine neoplasm with liver metastases. Hpb, 2018, 20, 197-203.	0.1	29
260	Minimally Invasive Versus Open Treatment for Benign Sporadic Insulinoma Comparison of Shortâ€Term and Longâ€Term Outcomes. World Journal of Surgery, 2018, 42, 3223-3230.	0.8	29
261	Poorly differentiated resectable pancreatic cancer: Is upfront resection worthwhile?. Surgery, 2012, 152, S112-S119.	1.0	28
262	mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 2016, 23, 883-891.	1.6	28
263	Risk and Protective Factors for Small Intestine Neuroendocrine Tumors: A Prospective Case-Control Study. Neuroendocrinology, 2016, 103, 531-537.	1.2	28
264	A systematic review and meta-analysis of spleen-preserving distal pancreatectomy with preservation or ligation of the splenic artery and vein. Journal of the Royal College of Surgeons of Edinburgh, 2016, 14, 109-118.	0.8	28
265	Multimodal treatment of resectable pancreatic ductal adenocarcinoma. Critical Reviews in Oncology/Hematology, 2017, 111, 152-165.	2.0	28
266	Human White Adipocytes Convert Into â€œRainbowâ€•Adipocytes In Vitro. Journal of Cellular Physiology, 2017, 232, 2887-2899.	2.0	28
267	A preoperative score to predict early death after pancreatic cancer resection. Digestive and Liver Disease, 2017, 49, 1050-1056.	0.4	28
268	Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment. Nuclear Medicine Communications, 2020, 41, 896-905.	0.5	28
269	Statin use improves survival in patients with pancreatic ductal adenocarcinoma: A meta-analysis. Digestive and Liver Disease, 2020, 52, 392-399.	0.4	28
270	Pancreatic acinar carcinoma shows a distinct pattern of chromosomal imbalances by comparative genomic hybridization. Genes Chromosomes and Cancer, 2000, 28, 294-299.	1.5	27

#	Article	IF	Citations
271	Contrastâ€Enhanced Ultrasonography in the Characterization of Pancreatic Mucinous Cystadenoma. Journal of Ultrasound in Medicine, 2004, 23, 1125-1129.	0.8	27
272	Middle-preserving pancreatectomy for multicentric body-sparing lesions of the pancreas. American Journal of Surgery, 2009, 198, e49-e53.	0.9	27
273	Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside. Cancer and Metastasis Reviews, 2014, 33, 321-331.	2.7	27
274	Surgical management of neuroendocrine tumors. Best Practice and Research in Clinical Endocrinology and Metabolism, 2016, 30, 93-102.	2.2	27
275	Functional Imaging in the Follow-Up of Enteropancreatic Neuroendocrine Tumors: Clinical Usefulness and Indications. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 1486-1494.	1.8	27
276	Ciprofloxacin Penetration in Pancreatic Juice. Chemotherapy, 1987, 33, 397-401.	0.8	26
277	Non-traumatic abdominal emergencies: imaging and intervention in acute pancreatic conditions. European Radiology, 2002, 12, 2407-2434.	2.3	26
278	Staging of digestive endocrine tumours using helical computed tomography and somatostatin receptor scintigraphy. Annals of Oncology, 2003, 14, 586-591.	0.6	26
279	Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategyâ€”A literature review. Critical Reviews in Oncology/Hematology, 2016, 98, 264-274.	2.0	26
280	Is the Real Prevalence of Pancreatic Neuroendocrine Tumors Underestimated? A Retrospective Study on a Large Series of Pancreatic Specimens. Neuroendocrinology, 2019, 109, 165-170.	1.2	26
281	Risk and Predictors of Postoperative Morbidity and Mortality After Pancreaticoduodenectomy for Pancreatic Neuroendocrine Neoplasms. Pancreas, 2019, 48, 504-509.	0.5	26
282	DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors. Scientific Reports, 2019, 9, 18614.	1.6	26
283	A systematic review and meta-analysis on the role of omental or falciform ligament wrapping during pancreaticoduodenectomy. Hpb, 2020, 22, 1227-1239.	0.1	26
284	Contrast-Enhanced Ultrasonography of Small Solid Pseudopapillary Tumors of the Pancreas. Journal of Ultrasound in Medicine, 2005, 24, 849-854.	0.8	25
285	Autoimmune pancreatitis: A challenging diagnostic puzzle for clinicians. Digestive and Liver Disease, 2010, 42, 92-98.	0.4	25
286	Adequacy of Lymph Node Retrieval for Ampullary Cancer and Its Association with Improved Staging and Survival. World Journal of Surgery, 2013, 37, 1397-1404.	0.8	25
287	B lymphocytes contribute to stromal reaction in pancreatic ductal adenocarcinoma. Oncolmmunology, 2020, 9, 1794359.	2.1	25
288	Factors Associated With the Risk of Progression of Low-Risk Branch-Duct Intraductal Papillary Mucinous Neoplasms. JAMA Network Open, 2020, 3, e2022933.	2.8	25

#	Article	IF	Citations
289	Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). Annals of Surgical Oncology, 2021, 28, 7506-7517.	0.7	25
290	Resectable Pancreatic Adenocarcinoma. Pancreas, 2008, 37, 265-268.	0.5	24
291	Systematic review and meta-analysis of prognostic role of splenic vessels infiltration in resectable pancreatic cancer. European Journal of Surgical Oncology, 2018, 44, 24-30.	0.5	24
292	The Impact of Neoadjuvant Treatment on Survival in Patients Undergoing Pancreatoduodenectomy With Concomitant Portomesenteric Venous Resection: An International Multicenter Analysis. Annals of Surgery, 2021, 274, 721-728.	2.1	24
293	The determinant factors of recurrence following resection for ductal pancreatic cancer. JOP: Journal of the Pancreas, 2007, 8, 132-40.	1.5	24
294	Role of somatostatin and somatostatin analogues in the treatment of gastrointestinal diseases: prevention of complications after pancreatic surgery.. Gut, 1994, 35, S20-S22.	6.1	23
295	Antimicrobial activity of human pancreatic juice and its interaction with antibiotics. Antimicrobial Agents and Chemotherapy, 1996, 40, 2099-2105.	1.4	23
296	Laparoscopic ileocecal resection for bowel endometriosis. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 1257-1262.	1.3	23
297	Alcohol Intake, Cigarette Smoking, and Body Mass Index in Patients with Alcohol-associated Pancreatitis. Journal of Clinical Gastroenterology, 2000, 31, 314-317.	1.1	22
298	Changes in pancreatic resection for chronic pancreatitis over 28 years in a single institution. British Journal of Surgery, 2002, 87, 428-433.	0.1	22
299	Outcomes of intraductal papillary mucinous neoplasm with â€œSendai-positiveâ€•criteria for resection undergoing non-operative management. Digestive and Liver Disease, 2013, 45, 584-588.	0.4	22
300	A multicenter survey on distal pancreatectomy in Italy: results of minimally invasive techniqueÂand variability of perioperative pathways. Updates in Surgery, 2014, 66, 253-263.	0.9	22
301	Diagnosis and treatment in chronic pancreatitis: an international survey and case vignette study. Hpb, 2017, 19, 978-985.	0.1	22
302	Ct radiomic features of pancreatic neuroendocrine neoplasms (panNEN) are robust against delineation uncertainty. Physica Medica, 2019, 57, 41-46.	0.4	22
303	Surgeon experience contributes to improved outcomes in pancreatoduodenectomies at high risk for fistula development. Surgery, 2021, 169, 708-720.	1.0	22
304	Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. Annals of Surgery, 2021, 274, 481-490.	2.1	22
305	Minimally invasive versus open distal pancreatectomy for pancreatic ductal adenocarcinoma (DIPLOMA): study protocol for a randomized controlled trial. Trials, 2021, 22, 608.	0.7	22
306	Preoperative assessment of nonfunctioning pancreatic endocrine tumours: role of MDCT and MRI. Radiologia Medica, 2013, 118, 1082-1101.	4.7	21

#	Article	IF	Citations
307	Insulin resistance is associated with the aggressiveness of pancreatic ductal carcinoma. Acta Diabetologica, 2016, 53, 945-956.	1.2	21
308	Robustness of CT radiomic features against image discretization and interpolation in characterizing pancreatic neuroendocrine neoplasms. Physica Medica, 2020, 76, 125-133.	0.4	21
309	Epidemiology, clinical features and diagnostic work-up of cystic neoplasms of the pancreas: Interim analysis of the prospective PANCY survey. Digestive and Liver Disease, 2020, 52, 547-554.	0.4	21
310	Preoperative risk stratification of postoperative pancreatic fistula: A risk-tree predictive model for pancreatoduodenectomy. Surgery, 2021, 170, 1596-1601.	1.0	21
311	Molecular pathology of intraductal papillary mucinous neoplasms of the pancreas. World Journal of Gastroenterology, 2014, 20, 10008.	1.4	21
312	Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors. JAMA Network Open, 2022, 5, e220290.	2.8	21
313	Prophylaxis for septic complications in acute necrotizing pancreatitis. Journal of Hepato-Biliary-Pancreatic Surgery, 2001, 8, 211-215.	2.0	20
314	Small intestinal neuroendocrine tumors with liver metastases and resection of the primary: Prognostic factors for decision making. International Journal of Surgery, 2015, 20, 58-64.	1.1	20
315	Interaction between human mature adipocytes and lymphocytes induces T-cell proliferation. Cytotherapy, 2015, 17, 1292-1301.	0.3	20
316	Effect of Diabetes on Survival after Resection of Pancreatic Adenocarcinoma. A Prospective, Observational Study. PLoS ONE, 2016, 11, e0166008.	1.1	20
317	Impact of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) single nucleotide polymorphisms on outcome in gastroenteropancreatic neuroendocrine neoplasms. PLoS ONE, 2018, 13, e0197035.	1.1	20
318	Dual Tracer 68Ga-DOTATOC and 18F-FDG PET Improve Preoperative Evaluation of Aggressiveness in Resectable Pancreatic Neuroendocrine Neoplasms. Diagnostics, 2021, 11, 192.	1.3	20
319	Efficacy and safety of rituximab for IgG4-related pancreato-biliary disease: A systematic review and meta-analysis. Pancreatology, 2021, 21, 1395-1401.	0.5	20
320	Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival. Annals of Surgical Oncology, 2021, 28, 8249-8260.	0.7	20
321	Medical treatment for gastro-entero-pancreatic neuroendocrine tumours. World Journal of Gastrointestinal Oncology, 2016, 8, 389.	0.8	20
322	Nowotwory neuroendokrynne Å¼oÅ‚Ä…dka i dwunastnicy z uwzglÄ™dnieniem gastrinoma (zasady postÄ™powania) Tj ETQq0 0 0 rgBT	0.3	20
323	Nowotwory neuroendokrynne jelita grubego â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡) Tj ETQq1 1 0.784314	0.3	20
324	Quality assessment of the guidelines on cystic neoplasms of the pancreas. Pancreatology, 2015, 15, 463-469.	0.5	19

#	Article	IF	Citations
325	Single-incision laparoscopic cholecystectomy versus traditional laparoscopic cholecystectomy performed by a single surgeon: findings of a randomized trial. Surgery Today, 2016, 46, 313-318.	0.7	19
326	Unmet needs in the international neuroendocrine tumor (NET) community: Assessment of major gaps from the perspective of patients, patient advocates and NET health care professionals. International Journal of Cancer, 2020, 146, 1316-1323.	2.3	19
327	Perspectives from Italy during the COVID-19 pandemic: nationwide survey-based focus on minimally invasive HPB surgery. Updates in Surgery, 2020, 72, 241-247.	0.9	19
328	Radical intended surgery for highly selected stage IV neuroendocrine neoplasms G3. American Journal of Surgery, 2020, 220, 284-289.	0.9	19
329	Circulating Neuroendocrine Gene Transcripts (NETest): A Postoperative Strategy for Early Identification of the Efficacy of Radical Surgery for Pancreatic Neuroendocrine Tumors. Annals of Surgical Oncology, 2020, 27, 3928-3936.	0.7	19
330	Ofloxacin penetration into bile and pancreatic juice. Journal of Antimicrobial Chemotherapy, 1989, 23, 805-807.	1.3	18
331	Pancreatic Pathology. , 2005, , 335-347.		18
332	Mucinous cystic carcinoma of the pancreas: a unique cell line and xenograft model of a preinvasive lesion. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 239-245.	1.4	18
333	Extent of Surgery and Implications of Transection Margin Status after Resection of IPMNs. Gastroenterology Research and Practice, 2014, 2014, 1-10.	0.7	18
334	Sunitinib in patients with pre-treated pancreatic neuroendocrine tumors: A real-world study. Pancreatology, 2018, 18, 198-203.	0.5	18
335	Combined 68Ga-DOTA-peptides and 18F-FDG PET in the diagnostic work-up of neuroendocrine neoplasms (NEN). Clinical and Translational Imaging, 2019, 7, 181-188.	1.1	18
336	Neuroendocrine Tumors (NETs) of the Minor Papilla/Ampulla. American Journal of Surgical Pathology, 2019, 43, 725-736.	2.1	18
337	Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis. Translational Oncology, 2019, 12, 1-7.	1.7	18
338	Development of a conceptual framework of recovery after abdominal surgery. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 2665-2674.	1.3	18
339	Review of the diagnosis and management of intraductal papillary mucinous neoplasms. United European Gastroenterology Journal, 2020, 8, 249-255.	1.6	18
340	Vascular resection during pancreatectomy for pancreatic head cancer: A technical issue or a prognostic sign?. Surgery, 2021, 169, 403-410.	1.0	18
341	R Status is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 4602-4612.	0.7	18
342	Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study. European Journal of Internal Medicine, 2021, 84, 63-67.	1.0	18

#	Article	IF	Citations
343	Nowotwory neuroendokrynne jelita cienkiego i wyrostka robaczkowego â€" zasady postÄ™powania (rekomendowane przez PolskÄ... SieÄ‡ GuzÃ³w Neuroendokrynnych). Endokrynologia Polska, 2017, 68, 223-236.	0.3	18
344	Antibacterial and mezlocillin-enhancing activity of pure human pancreatic fluid. International Journal of Gastrointestinal Cancer, 1991, 10, 293-297.	0.4	17
345	Infection prevention in necrotizing pancreatitis: an old challenge with new perspectives. Journal of Hospital Infection, 2001, 49, 4-8.	1.4	17
346	â€œPancProâ€•as a tool for selecting families eligible for pancreatic cancer screening: An Italian study of incident cases. Digestive and Liver Disease, 2012, 44, 585-588.	0.4	17
347	Outcomes of Elective and Emergency Conversion in Minimally Invasive Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma: An International Multicenter Propensity Score-matched Study. Annals of Surgery, 2021, 274, e1001-e1007.	2.1	17
348	A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. Updates in Surgery, 2020, 72, 39-45.	0.9	17
349	Evolving pancreatic cancer treatment: From diagnosis to healthcare management. Critical Reviews in Oncology/Hematology, 2022, 169, 103571.	2.0	17
350	Treatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study. Hpb, 2013, 15, 935-943.	0.1	16
351	Time trends in the treatment and prognosis of resectable pancreatic cancer in a large tertiary referral centre. Hpb, 2013, 15, 958-964.	0.1	16
352	Evaluation of cost-effectiveness among open, laparoscopic and robotic distal pancreatectomy: A systematic review and meta-analysis. American Journal of Surgery, 2021, 222, 513-520.	0.9	16
353	Prediction of Early Distant Recurrence in Upfront Resectable Pancreatic Adenocarcinoma: A Multidisciplinary, Machine Learning-Based Approach. Cancers, 2021, 13, 4938.	1.7	16
354	Surgical strategy in the treatment of pancreatic neuroendocrine tumors. JOP: Journal of the Pancreas, 2006, 7, 150-6.	1.5	16
355	Ampulla of vater cancers: T-stage and histological subtype but not Dpc4 expression predict prognosis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 441, 19-24.	1.4	15
356	Borderline resectable pancreatic cancer: More than an anatomical concept. Digestive and Liver Disease, 2017, 49, 223-226.	0.4	15
357	Pancreatic enzyme replacement therapy after gastric resection: An update. Digestive and Liver Disease, 2018, 50, 1-5.	0.4	15
358	Diagnostic strategy with a solid pancreatic mass. Presse Medicale, 2019, 48, e125-e145.	0.8	15
359	The size of well differentiated pancreatic neuroendocrine tumors correlates with Ki67 proliferative index and is not associated with age. Digestive and Liver Disease, 2019, 51, 735-740.	0.4	15
360	Outcomes after distal pancreatectomy for neuroendocrine neoplasms: a retrospective comparison between minimally invasive and open approach using propensity score weighting. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 165-173.	1.3	15

#	Article	IF	Citations
361	Recurrence after surgical resection of pancreatic cancer: the importance of postoperative complications beyond tumor biology. Hpb, 2021, 23, 1666-1673.	0.1	15
362	The role of acinar content at pancreatic resection margin in the development of postoperative pancreatic fistula and acute pancreatitis after pancreaticoduodenectomy. Surgery, 2021, 170, 1215-1222.	1.0	15
363	Penetration of mezlocillin into pancreatic Juice. Journal of Antimicrobial Chemotherapy, 1986, 17, 397-397.	1.3	14
364	Dpc4 is expressed in virtually all primary and metastatic pancreatic endocrine carcinomas. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2002, 440, 155-159.	1.4	14
365	Rectal Indomethacin to Prevent Post-ERCP Pancreatitis. New England Journal of Medicine, 2012, 367, 277-279.	13.9	14
366	The role of 18fluoro-deoxyglucose positron emission tomography/computed tomography in resectable pancreatic cancer. Digestive and Liver Disease, 2014, 46, 744-749.	0.4	14
367	Surgical management of the pancreatic stump following pancreato-duodenectomy. Journal of Visceral Surgery, 2016, 153, 193-202.	0.4	14
368	Gastro-entero-pancreatic neuroendocrine neoplasia: The rules for non-operative management. Surgical Oncology, 2020, 35, 141-148.	0.8	14
369	Positive neck margin at frozen section analysis is a significant predictor of tumour recurrence and poor survival after pancreatodudenectomy for pancreatic cancer. European Journal of Surgical Oncology, 2020, 46, 1524-1531.	0.5	14
370	Diagnosis and treatment of exocrine pancreatic insufficiency in chronic pancreatitis: An international expert survey and case vignette study. Pancreatology, 2022, 22, 457-465.	0.5	14
371	Continuous peritoneal dialysis in acute experimental pancreatitis in dogs. International Journal of Gastrointestinal Cancer, 1989, 5, 69-75.	0.4	13
372	A novel germline mutation, P48T, in theCDKN2A/p16 gene in a patient with pancreatic carcinoma. Human Mutation, 2000, 16, 447-448.	1.1	13
373	Value of regional lymphadenectomy in pancreatic cancer. Hpb, 2005, 7, 87-92.	0.1	13
374	Insulinomaâ€”new insights into an old disease. Nature Reviews Endocrinology, 2009, 5, 300-302.	4.3	13
375	B-Cell Lymphoma Presenting as Acute Pancreatitis. Pancreatology, 2011, 11, 553-556.	0.5	13
376	Glial-Like Differentiation Potential of Human Mature Adipocytes. Journal of Molecular Neuroscience, 2015, 55, 91-98.	1.1	13
377	Diabetes associated with pancreatic ductal adenocarcinoma is just diabetes: Results of a prospective observational study in surgical patients. Pancreatology, 2016, 16, 844-852.	0.5	13
378	Methotrexate as Induction of Remission Therapy for Type 1 Autoimmune Pancreatitis. American Journal of Gastroenterology, 2019, 114, 831-833.	0.2	13

#	Article	IF	Citations
379	Evidence of a common cell origin in a case of pancreatic mixed intraductal papillary mucinous neoplasmâ€“neuroendocrine tumor. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 1215-1219.	1.4	13
380	Preoperative predictive factors of laparoscopic distal pancreatectomy difficulty. Hpb, 2020, 22, 1766-1774.	0.1	13
381	Histopathological and Immunophenotypic Changes of Pancreatic Neuroendocrine Tumors after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT). Endocrine Pathology, 2020, 31, 119-131.	5.2	13
382	Prognostic Role of Examined and Positive Lymph Nodes after Distal Pancreatectomy for Non-Functioning Neuroendocrine Neoplasms. Neuroendocrinology, 2021, 111, 728-738.	1.2	13
383	Surgical Principles in the Management of Pancreatic Neuroendocrine Neoplasms. Current Treatment Options in Oncology, 2020, 21, 48.	1.3	13
384	Surgery for Intraductal Papillary Mucinous Neoplasms of the Pancreas: Preoperative Factors Tipping the Scale of Decision-Making. Annals of Surgical Oncology, 2022, 29, 3206-3214.	0.7	13
385	Effects of glucocorticoids on B-cell subpopulations in patients with IgG4-related disease. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 159-166.	0.4	13
386	Previous Cholecystectomy, Gastrectomy, and Diabetes Mellitus are not Crucial Risk Factors for Pancreatic Cancer in Patients with Chronic Pancreatitis. Pancreas, 2001, 23, 364-367.	0.5	12
387	Carcinoma of pancreatic body and tail: are there improvements in diagnosis and treatment modalities over the past decade?. Digestive and Liver Disease, 2003, 35, 421-427.	0.4	12
388	Management of rectosigmoid obstruction due to severe bowel endometriosis. Updates in Surgery, 2014, 66, 59-64.	0.9	12
389	Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 301-310.	1.8	12
390	Allo- and auto-percutaneous intra-portal pancreatic islet transplantation (PIPIT) for diabetes cure and prevention: the role of imaging and interventional radiology. Gland Surgery, 2018, 7, 117-131.	0.5	12
391	Postoperative Outcomes and Functional Recovery After Preoperative Combination Chemotherapy for Pancreatic Cancer: A Propensity Score-Matched Study. Frontiers in Oncology, 2019, 9, 1299.	1.3	12
392	A four-step method to centralize pancreatic surgery, accounting for volume, performance and access to care. Hpb, 2021, 23, 1095-1104.	0.1	12
393	A Preoperative Clinical Risk Score Including C-Reactive Protein Predicts Histological Tumor Characteristics and Patient Survival after Surgery for Sporadic Non-Functional Pancreatic Neuroendocrine Neoplasms: An International Multicenter Cohort Study. Cancers, 2020, 12, 1235.	1.7	12
394	Practical recommendations for the management of patients with gastroenteropancreatic and thoracic (carcinoid) neuroendocrine neoplasms in the COVID-19 era. European Journal of Cancer, 2021, 144, 200-214.	1.3	12
395	Portal vein resection during pancreaticoduodenectomy for pancreatic neuroendocrine tumors. An international multicenter comparative study. Surgery, 2021, 169, 1093-1101.	1.0	12
396	A tug-of-war in intraductal papillary mucinous neoplasms management: Comparison between 2017 International and 2018 European guidelines. Digestive and Liver Disease, 2021, 53, 998-1003.	0.4	12

#	Article	IF	Citations
397	Presentation, diagnostic features and glucose handling in a monocentric series of insulinomas. Journal of Endocrinological Investigation, 2013, 36, 753-8.	1.8	12
398	Isolated blunt duodenal trauma: delayed diagnosis and favorable outcome with "quadruple tube" decompression. JOP: Journal of the Pancreas, 2007, 8, 617-20.	1.5	12
399	ENETS standardized (synoptic) reporting for endoscopy in neuroendocrine tumors. Journal of Neuroendocrinology, 2022, 34, e13105.	1.2	12
400	Absence of mutations in the transforming growth factor-Î2 inducible early gene 1, TIEG1, in pancreatic cancer. Cancer Letters, 2002, 183, 179-183.	3.2	11
401	Discussion on prophylactic antibiotic treatment in patients with predicted severe pancreatitis: A placebo-controlled, double-blind trial. Gastroenterology, 2004, 127, 1015-1016.	0.6	11
402	Congenital bile duct cyst (BDC) is a more indolent disease in children compared to adults, except for Todani type IV-A BDC: results of the European multicenter study of the French Surgical Association. Hpb, 2016, 18, 529-539.	0.1	11
403	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors. Cancer Medicine, 2017, 6, 1493-1499.	1.3	11
404	miR-204 is associated with an endocrine phenotype in human pancreatic islets but does not regulate the insulin mRNA through MAFA. Scientific Reports, 2017, 7, 14051.	1.6	11
405	Long-Term Pancreatic Functional Impairment after Surgery for Neuroendocrine Neoplasms. Journal of Clinical Medicine, 2019, 8, 1611.	1.0	11
406	Adjuvant chemoradiation in pancreatic cancer: impact of radiotherapy dose on survival. BMC Cancer, 2019, 19, 569.	1.1	11
407	Diabetes-free survival after extended distal pancreatectomy and islet auto transplantation for benign or borderline/malignant lesions of the pancreas. American Journal of Transplantation, 2019, 19, 920-928.	2.6	11
408	RNA Extraction from Endoscopic Ultrasound-Acquired Tissue of Pancreatic Cancer Is Feasible and Allows Investigation of Molecular Features. Cells, 2020, 9, 2561.	1.8	11
409	High sensitivity of ROSE-supported ERCP-guided brushing for biliary strictures. Endoscopy International Open, 2021, 09, E363-E370.	0.9	11
410	The effect of high intraoperative blood loss on pancreatic fistula development after pancreatoduodenectomy: An international, multi-institutional propensity score matched analysis. Surgery, 2021, 170, 1195-1204.	1.0	11
411	Main Duct Thresholds for Malignancy Are Different in Intraductal Papillary Mucinous Neoplasms of the Pancreatic Head and Body-Tail. Clinical Gastroenterology and Hepatology, 2020, , .	2.4	11
412	Diagnostic accuracy of EUS-FNA in the evaluation of pancreatic neuroendocrine neoplasms grading: Possible clinical impact of misclassification. Endoscopic Ultrasound, 2021, 10, 372.	0.6	11
413	Identification of patients with branch-duct intraductal papillary mucinous neoplasm and very low risk of cancer: multicentre study. British Journal of Surgery, 2022, 109, 617-622.	0.1	11
414	The role of surgery in the major early complications of severe acute pancreatitis. European Journal of Gastroenterology and Hepatology, 1997, 9, 131-136.	0.8	10

#	Article	IF	Citations
415	Evaluation of UICC TNM classification for pancreatic cancer. International Journal of Gastrointestinal Cancer, 1997, 21, 111-118.	0.4	10
416	Evaluation of lanreotide effects on human exocrine pancreatic secretion after a single dose: preliminary study. Digestive and Liver Disease, 2002, 34, 127-132.	0.4	10
417	Acoustic Radiation Force Impulse Ultrasound Imaging of Pancreatic Cystic Lesions. Pancreas, 2010, 39, 939-940.	0.5	10
418	Lgr5 expression, cancer stem cells and pancreatic cancer: results from biological and computational analyses. Future Oncology, 2015, 11, 1037-1045.	1.1	10
419	Biosafety evidence for human dedifferentiated adipocytes. Journal of Cellular Physiology, 2015, 230, 1525-1533.	2.0	10
420	SUVmax after (18)fluoro-deoxyglucose positron emission tomography/computed tomography: A tool to define treatment strategies in pancreatic cancer. Digestive and Liver Disease, 2018, 50, 84-90.	0.4	10
421	Italian registry of families at risk of pancreatic cancer: AISP Familial Pancreatic Cancer Study Group. Digestive and Liver Disease, 2020, 52, 1126-1130.	0.4	10
422	Reappraisal of a 2-Cm Cut-off Size for the Management of Cystic Pancreatic Neuroendocrine Neoplasms. Annals of Surgery, 2021, 273, 973-981.	2.1	10
423	Pancreatic Adenocarcinoma: Improving Prevention and Survivorship. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 301-310.	1.8	10
424	Local treatment for focal progression in metastatic neuroendocrine tumors. Endocrine-Related Cancer, 2019, 26, 405-409.	1.6	10
425	Molecular Targeted Therapy in Enteropancreatic Neuroendocrine Tumors: From Biology to Clinical Practice. Current Medicinal Chemistry, 2014, 21, 1017-1025.	1.2	10
426	Early biochemical predictors of clinically relevant pancreatic fistula after distal pancreatectomy: a role for serum amylase and C-reactive protein. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 5431-5441.	1.3	10
427	Pancreaticoduodenal Graft in the Rat: An Original Microsurgical Technique. European Surgical Research, 1989, 21, 162-167.	0.6	9
428	Maldi-TOF analysis of portal sera of pancreatic cancer patients: identification of diabetogenic and antidiabetogenic peptides. Clinica Chimica Acta, 2004, 343, 119-127.	0.5	9
429	Implications of the new histological classification (WHO 2010) for pancreatic neuroendocrine neoplasms. Annals of Oncology, 2012, 23, 1928.	0.6	9
430	The natural history of a branch-duct intraductal papillary mucinous neoplasm of the pancreas. Surgery, 2014, 155, 578-579.	1.0	9
431	Standards for reporting on surgery for chronic pancreatitis: a report from the International Study Group for Pancreatic Surgery (ISGPS). Surgery, 2020, 168, 101-105.	1.0	9
432	Total pancreatectomy sequelae and quality of life: results of islet autotransplantation as a possible mitigation strategy. Updates in Surgery, 2021, 73, 1237-1246.	0.9	9

#	Article	IF	Citations
433	Spectrum of magnetic resonance imaging findings in pancreatic and other abdominal manifestations of Von Hippel-Lindau disease in a series of 23 patients: a pictorial review. JOP: Journal of the Pancreas, 2014, 15, 1-18.	1.5	9
434	EZH2 Inhibition as New Epigenetic Treatment Option for Pancreatic Neuroendocrine Neoplasms (PanNENs). Cancers, 2021, 13, 5014.	1.7	9
435	Rifampicin concentrations in pancreatic juice. Journal of Antimicrobial Chemotherapy, 1985, 16, 129-130.	1.3	8
436	Does the Extent of Lymphatic Resection Affect the Outcome in Pancreatic Cancer?. Digestion, 1997, 58, 536-541.	1.2	8
437	In vivo Octreotide Administration Acutely Reduces Exocrine Granule Size in the Human Pancreas. Pancreatology, 2001, 1, 30-35.	0.5	8
438	Is CA 19-9 a screening marker?. Digestive and Liver Disease, 2009, 41, 325-327.	0.4	8
439	An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change?. Anti-Cancer Drugs, 2010, 21, 459-464.	0.7	8
440	Hyperinsulinemic hypoglycemia associated with ectopic Cushingâ€™s syndrome due to a pancreatic endocrine tumor in a Type 2 diabetes mellitus patient: Clinical implications of a rare association. Journal of Endocrinological Investigation, 2011, 34, 175-179.	1.8	8
441	Treatment trends in metastatic pancreatic cancer patients: Is it time to change?. Digestive and Liver Disease, 2011, 43, 225-230.	0.4	8
442	Treatment of branch-duct intraductal papillary mucinous neoplasms of the pancreas: state of the art. Updates in Surgery, 2016, 68, 265-271.	0.9	8
443	Gene expression analysis of embryonic pancreas development master regulators and terminal cell fate markers in resected pancreatic cancer: A correlation with clinical outcome. Pancreatology, 2018, 18, 945-953.	0.5	8
444	Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2020, 85, 641-650.	1.1	8
445	Resectability of Pancreatic Cancer Is in the Eye of the Observer. Annals of Surgery Open, 2021, 2, e087.	0.7	8
446	Pancreatic cystic neoplasms: What is the most cost-effective follow-up strategy?. Endoscopic Ultrasound, 2018, 7, 319.	0.6	8
447	New era for pancreatic endoscopic ultrasound: From imaging to molecular pathology of pancreatic cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 933-945.	0.8	8
448	EUS-guided gallbladder drainage and subsequent peroral endoscopic cholecystolithotomy: A tool to reduce chemotherapy discontinuation in neoplastic patients?. VideoGIE, 2022, 7, 120-127.	0.3	8
449	The impact of nutritional status on pancreatic cancer therapy. Expert Review of Anticancer Therapy, 2022, 22, 155-167.	1.1	8
450	Pancreatic Surgery. Frontiers of Hormone Research, 2015, 44, 139-148.	1.0	7

#	Article	IF	Citations
451	Single-centre experience of extending indications for percutaneous intraportal islet autotransplantation (PIPIAT) after pancreatic surgery to prevent diabetes: feasibility, radiological aspects, complications and clinical outcome. British Journal of Radiology, 2016, 89, 20160246.	1.0	7
452	How should incidental NEN of the pancreas and gastrointestinal tract be followed?. Reviews in Endocrine and Metabolic Disorders, 2018, 19, 139-144.	2.6	7
453	Endoscopic ultrasound appearance of pancreatic serotonin-staining neuroendocrine neoplasms. Pancreatology, 2018, 18, 792-798.	0.5	7
454	Application of minimally invasive pancreatic surgery: an Italian survey. Updates in Surgery, 2019, 71, 97-103.	0.9	7
455	The impact of minimally invasive surgery on hospital readmissions, emergency department visits and functional recovery after distal pancreatectomy. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 5740-5751.	1.3	7
456	Before sentinel bleeding: early prediction of postpancreatectomy hemorrhage (PPH) with a CT-based scoring system. European Radiology, 2021, 31, 6879-6888.	2.3	7
457	Impact of care pathway adherence on recovery following distal pancreatectomy within an enhanced recovery program. Hpb, 2021, 23, 1815-1823.	0.1	7
458	Efficacy of Endoscopic Ultrasound-Guided Ablation with the HybridTherm Probe in Locally Advanced or Borderline Resectable Pancreatic Cancer: A Phase II Randomized Controlled Trial. Cancers, 2021, 13, 4512.	1.7	7
459	Surgical management of pancreatic neuroendocrine neoplasms. Annals of Saudi Medicine, 2014, 34, 1-5.	0.5	7
460	Pancreaticoduodenectomy in octogenarians: The importance of â€œbiological ageâ€•on clinical outcomes. Surgical Oncology, 2022, 40, 101688.	0.8	7
461	Clinical Management of Neuroendocrine Neoplasms in Clinical Practice: A Formal Consensus Exercise. Cancers, 2022, 14, 2501.	1.7	7
462	Assessment and Treatment of Severe Pancreatitis. Digestion, 1999, 60, 5-8.	1.2	6
463	Symptomatic stone in the duodenum after gastrectomy. Surgery, 2001, 129, 238-239.	1.0	6
464	Different reconstruction techniques after pancreatoduodenectomy do not affect clinical and patient reported outcomes. Advances in Medical Sciences, 2014, 59, 151-155.	0.9	6
465	Salvage Islet Auto Transplantation After Relaparatomy. Transplantation, 2017, 101, 2492-2500.	0.5	6
466	Defining rules for increasingly personalized treatments. Nature Reviews Clinical Oncology, 2017, 14, 80-82.	12.5	6
467	Surveillance of Cystic Lesions of the Pancreas: Whom and How to Survey?. Visceral Medicine, 2018, 34, 202-205.	0.5	6
468	Association between preoperative Vasostatin-1 and pathological features of aggressiveness in localized nonfunctioning pancreatic neuroendocrine tumors (NF-PanNET). Pancreatology, 2019, 19, 57-63.	0.5	6

#	Article	IF	Citations
469	The Oncologic Impact of Pancreatic Fistula After Distal Pancreatectomy for Pancreatic Ductal Adenocarcinoma of the Body and the Tail: A Multicenter Retrospective Cohort Analysis. Annals of Surgical Oncology, 2021, 28, 3171-3183.	0.7	6
470	Utility of the â€œ2019 ACR/EULAR classification criteriaâ€•for the management of patients with IgG4-related disease. Seminars in Arthritis and Rheumatism, 2021, 51, 761-765.	1.6	6
471	Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer. Endoscopy International Open, 2020, 08, E1511-E1519.	0.9	6
472	Disease-free survival as a measure of overall survival in resected pancreatic endocrine neoplasms. Endocrine-Related Cancer, 2020, 27, 275-283.	1.6	6
473	Gemcitabine and continuous infusion of 5-fluorouracil in locally advanced and metastatic pancreatic cancer: a phase I-II study. Anticancer Research, 2004, 24, 2107-12.	0.5	6
474	Intraductal papillary mucinous tumors of the pancreas. Surgical treatment: at what point should we stop?. JOP: Journal of the Pancreas, 2005, 6, 112-7.	1.5	6
475	Prospective study of the detection and treatment of small tumors of the head of the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery, 1995, 2, 347-351.	2.0	5
476	Allelotype of ampulla of Vater cancer: highly frequent involvement of chromosome 11. Journal of Cancer Research and Clinical Oncology, 2004, 130, 339-345.	1.2	5
477	The Role of Hyponatraemia Before Surgery in Patients With Radical Resected Pancreatic Cancer. Clinical Medicine Insights: Oncology, 2020, 14, 117955492093660.	0.6	5
478	Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma: Legend or Scientific Evidence?. Annals of Surgical Oncology, 2021, 28, 2312-2322.	0.7	5
479	Endoscopic ultrasound-guided gastrojejunostomy does not prevent pancreaticoduodenectomy after long-term symptom-free neoadjuvant treatment. Endoscopy, 2021, , .	1.0	5
480	Improved survival after pancreatic re-resection of positive neck margin in pancreatic cancer patients. A systematic review and network meta-analysis. European Journal of Surgical Oncology, 2021, 47, 1258-1266.	0.5	5
481	Development of a quality of life questionnaire for patients with pancreatic neuroendocrine tumours (the PANNET module). Journal of Neuroendocrinology, 2022, 34, e13097.	1.2	5
482	Differential EUS findings in focal type 1 autoimmune pancreatitis and pancreatic cancer: A proof-of-concept study. Endoscopic Ultrasound, 2022, 11, 216.	0.6	5
483	Adjuvant Chemoradiation in Pancreatic Cancer: A Pooled Analysis in Elderly (â‰¥75 years) Patients. Anticancer Research, 2015, 35, 3441-6.	0.5	5
484	Trial sequential analysis of randomized controlled trials on neoadjuvant therapy for resectable pancreatic cancer. European Journal of Surgical Oncology, 2022, 48, 1994-2001.	0.5	5
485	Ampullary Neuroendocrine Neoplasms: Identification of Prognostic Factors in a Multicentric Series of 119 Cases. Endocrine Pathology, 2022, 33, 274-288.	5.2	5
486	A polymorphic variant in telomere maintenance is associated with worrisome features and high-risk stigmata development in IPMNs. Carcinogenesis, 2022, 43, 728-735.	1.3	5

#	Article	IF	Citations
487	Prophylactic pylorus-preserving gastric transposition in unresectable carcinoma of the pancreatic head. American Journal of Surgery, 2004, 187, 564-566.	0.9	4
488	Improving cytological diagnosis of pancreatic cysts: Is it clinically necessary or just the latest fashion?. Digestive and Liver Disease, 2010, 42, 844-845.	0.4	4
489	Pancreatic Ductal Adenocarcinoma. Annals of Surgery, 2017, 266, e108-e109.	2.1	4
490	Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2017, 18, 419-449.	0.6	4
491	68Ga-DOTA-peptides PET/MRI in pancreatico-duodenal neuroendocrine tumours: a flash pictorial essay on assets and lacks. Clinical and Translational Imaging, 2019, 7, 363-371.	1.1	4
492	Pattern of disease recurrence and treatment after surgery for nonfunctioning well-differentiated pancreatic neuroendocrine tumors. Surgery, 2020, 168, 816-824.	1.0	4
493	Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 european patientsâ€”The ENETS registry.. Journal of Clinical Oncology, 2018, 36, 4095-4095.	0.8	4
494	Survival after active surveillance versus upfront surgery for incidental small pancreatic neuroendocrine tumours. British Journal of Surgery, 2022, 109, 733-738.	0.1	4
495	Pancreatic resections for benign intraductal papillary mucinous neoplasms: Collateral damages from friendly fire. Surgery, 2022, 172, 1202-1209.	1.0	4
496	Early graft injurie, after pancreatic transplantation insyngeneic rats. International Journal of Gastrointestinal Cancer, 1991, 8, 345-353.	0.4	3
497	Role of Somatostatin and Its Analogues in Gastrointestinal Fistulas, Ascites and Pancreatic Pseudocysts. Digestive Surgery, 1994, 11, 451-455.	0.6	3
498	Justifying vein resection with pancreatoduodenectomy. Lancet Oncology, The, 2016, 17, e177-e178.	5.1	3
499	Duodeno-jejunal or gastro-enteric leakage after pancreatic resection: a caseâ€“control study. Updates in Surgery, 2019, 71, 295-303.	0.9	3
500	Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours. European Journal of Surgical Oncology, 2019, 45, 46-51.	0.5	3
501	The Applicability of a Checklist for the Diagnosis and Treatment of Exocrine Pancreatic Insufficiency. Pancreas, 2020, 49, 793-798.	0.5	3
502	Pancreatic fistula after pancreaticoduodenectomyâ€”does surgical technique matter?. Annals of Translational Medicine, 2020, 8, 669-669.	0.7	3
503	Screening for pancreatic cancerâ€”a compelling challenge. Hepatobiliary Surgery and Nutrition, 2021, 10, 264-266.	0.7	3
504	Indications to total pancreatectomy for positive neck margin after partial pancreatectomy: a review of a slippery ground. Updates in Surgery, 2021, 73, 1219-1229.	0.9	3

#	Article	IF	Citations
505	Total pancreatectomy: how, when and why?. Updates in Surgery, 2021, 73, 1203-1204.	0.9	3
506	Prognosis of Upfront Surgery for Pancreatic Cancer: A Systematic Review and Meta-Analysis of Prospective Studies. Frontiers in Oncology, 2021, 11, 812102.	1.3	3
507	Clinical and economic validation of grade B postoperative pancreatic fistula subclassification. Surgery, 2022, 171, 846-853.	1.0	3
508	Feasibility of therapeutic endoscopic ultrasound in the bridge-to-surgery scenario: The example of pancreatic adenocarcinoma. World Journal of Gastroenterology, 2022, 28, 976-984.	1.4	3
509	Duodenal Gastric Metaplasia and Duodenal Neuroendocrine Neoplasms: More Than a Simple Coincidence?. Journal of Clinical Medicine, 2022, 11, 2658.	1.0	3
510	Intraductal papillary mucinous neoplasms of the biliary and pancreatic ductsâ€"A shape shifting outlook into an increasingly recognized disease. Digestive and Liver Disease, 2012, 44, 183-184.	0.4	2
511	Randomized phase 2 trial of nab-paclitaxel plus gemcitabine, Â± capecitabine, cisplatin (PAXG regimen) in unresectable or borderline resectable pancreatic adenocarcinoma. Annals of Oncology, 2016, 27, vi230.	0.6	2
512	Somatostatin analogs: is one better than other?. Therapeutic Advances in Medical Oncology, 2017, 9, 817-819.	1.4	2
513	Pancreatic metastasis of papillary thyroid carcinoma with an intraductal growth pattern. Endoscopy, 2020, 52, E452-E453.	1.0	2
514	ASO Author Reflections: Circulating Neuroendocrine Gene Transcripts (NETest): A Promising Biomarker for Pancreatic Neuroendocrine Tumours (PanNET). Annals of Surgical Oncology, 2020, 27, 3937-3938.	0.7	2
515	Low-frequency of RABL3 pathogenetic variants in hereditary and familial pancreatic cancer. Digestive and Liver Disease, 2021, 53, 519-521.	0.4	2
516	Proclivity to Explore Locally Advanced Pancreas Cancer Is Not Associated with Surgeon Volume. Journal of Gastrointestinal Surgery, 2021, 25, 2562-2571.	0.9	2
517	Evaluation of factors predicting loss of benefit provided by laparoscopic distal pancreatectomy compared to open approach. Updates in Surgery, 2021, , 1.	0.9	2
518	Which is the best pancreatic anastomosis?. Minerva Chirurgica, 2019, 74, 241-252.	0.8	2
519	How to Select Patients Affected by Neuroendocrine Neoplasms for Surgery. Current Oncology Reports, 2022, 24, 227-239.	1.8	2
520	To what extent is surgery superior to endoscopic therapy in the management of chronic pancreatitis?. Italian Journal of Gastroenterology and Hepatology, 1998, 30, 571-9.	0.5	2
521	The Impact of CT-Assessed Liver Steatosis on Postoperative Complications After Pancreaticoduodenectomy for Cancer. Annals of Surgical Oncology, 2022, 29, 7063-7073.	0.7	2
522	Exâ€vivo investigation of radiofrequency ablation in pancreatic adenocarcinoma after neoadjuvant chemotherapy. DEN Open, 2023, 3, .	0.5	2

#	Article	IF	Citations
523	Role of unlabelled somatostatin analogues in the prevention of complications after elective pancreatic and peripancreatic surgery: a critical review. Digestive and Liver Disease, 2004, 36, S121-S127.	0.4	1
524	SILS cholecystectomy, early experience of a single institution: pilot study of 21 cases. Updates in Surgery, 2012, 64, 145-148.	0.9	1
525	Radiolabelled somatostatin analogue treatment in gastroenteropancreatic neuroendocrine tumours: factors associated with response and suggestions for therapeutic sequence: response to comments by Ezziddin et al.. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 176-177.	3.3	1
526	Comment on â€œPredicting aggressive behavior in nonfunctioning pancreatic neuroendocrineâ€• Surgery, 2014, 155, 582-584.	1.0	1
527	Surveillance for Pancreatic Cancer in High-Risk Individuals: First-Round Screening Results of a Multicentric Italian Program. Gastroenterology, 2017, 152, S1291.	0.6	1
528	Role of Minimally Invasive Surgery in the Treatment of Pancreatic Neuroendocrine Tumors. Updates in Surgery Series, 2018, , 141-147.	0.0	1
529	No evidence of pancreatic ductal adenocarcinoma specific autoantibodies to Ezrin in a liquid phase LIPS immunoassay. Cancer Biomarkers, 2018, 22, 351-357.	0.8	1
530	P.03.15 APPLICABILITY OF A CHECKLIST FOR THE DIAGNOSIS AND TREATMENT OF SEVERE EXOCRINE PANCREATIC INSUFFICIENCY (EPI). PRELIMINARY RESULTS OF AN EPI ITALIAN REGISTRY (EPITALY). Digestive and Liver Disease, 2019, 51, e170.	0.4	1
531	Comment on â€œPrognostic Factors of Survival After Neoadjuvant Treatment and Resection for Initially Unresectable Pancreatic Cancerâ€• What Is Good for the Surgeon Is Just as Good for the Patient?. Annals of Surgery, 2020, 271, e106-e107.	2.1	1
532	The Italian National Registry for minimally invasive pancreatic surgery: an initiative of the Italian Group of Minimally Invasive Pancreas Surgery (IGoMIPS). Updates in Surgery, 2020, 72, 379-385.	0.9	1
533	ASO Author Reflections: Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 2323-2324.	0.7	1
534	ASO Author Reflections: R Status Is a Relevant Prognostic Factor for Recurrence and Survival After Pancreatic Head Resection for Ductal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 4613-4614.	0.7	1
535	The impact of preoperative anemia on pancreatic resection outcomes. Hpb, 2022, 24, 717-726.	0.1	1
536	Pancreatic ductal adenocarcinoma in 2017: Time to change the therapeutic algorithm?. Endoscopic Ultrasound, 2017, 6, 62.	0.6	1
537	Radiotherapy and chemotherapy in pancreatic cancer. Topical issues and future perspectives. JOP: Journal of the Pancreas, 2006, 7, 122-30.	1.5	1
538	The use of ace inhibitors influences the risk of progression of BD-IPMNs under follow-up. Pancreatology, 2022, , .	0.5	1
539	Cancer of the Papilla of Vater: Preoperative Cryostatic Examination of Endoscopic Biopsies to Reduce Risk and Save Time and Money. Digestive Surgery, 1995, 12, 256-258.	0.6	0
540	Diagnosis and Differential Diagnosis of Pancreatic Cystic Tumors. , 0, , 488-496.		0

#	Article	IF	Citations
541	How useful is somatostatin at reducing complications associated with pancreatic surgery?. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 134-135.	1.7	0
542	A case of intraductal papillary mucinous tumour following recurrent attacks of pancreatitis lasting 26 years. Digestive and Liver Disease, 2007, 39, 585-588.	0.4	0
543	Neuroendocrine Tumors. , 0, , 564-668.		0
544	Laparoscopic Colorectal Surgery for Bowel Endometriosis With Transvaginal Resection and Specimen Extraction: Perioperative Results in 40 Consecutive Patients. Gastroenterology, 2011, 140, S-1030.	0.6	0
545	Early Postoperative Outcomes After Laparoscopic Segmental Colorectal Resection for Endometriosis: The Impact of Surgical Experience. Gastroenterology, 2011, 140, S-1030.	0.6	0
546	Advanced Digestive Endocrine Tumors: Prognostic Factors Analysis and Patients Stratification According to Metastatic Status. Gastroenterology, 2011, 140, S-873.	0.6	0
547	Re: â€œLong-term comparison of laparoscopy-assisted distal gastrectomy and open distal gastrectomy in advanced gastric cancerâ€•(Surg Endosc (2010) 24:1:63â€“67). Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 3050-3051.	1.3	0
548	Questions About Branch-Duct IPMNs With Sendai Negative Criteria. Annals of Surgery, 2014, 259, e42.	2.1	0
549	Double-stapled anastomosis versus mucosectomy and handsewn anastomosis in ileal pouch-anal anastomosis for ulcerative colitis or familial adenomatous polyposis. The Cochrane Library, 0, , .	1.5	0
550	Prognostic impact of the cumulative dose and dose intensity of everolimus in patients with pancreatic neuroendocrine tumors (PNETs). Annals of Oncology, 2016, 27, vi145.	0.6	0
551	Reassessment of proliferative activity at disease progression in neuroendocrine neoplasms. Annals of Oncology, 2016, 27, vi143.	0.6	0
552	597 Molecular Markers Help Define Cyst Type in the Pancreas: An International, Multicenter Study of Over 300 Cysts. Gastroenterology, 2016, 150, S121.	0.6	0
553	Sa1389 Clinical Usefulness of Functional Imaging Tests in the Follow-Up of Digestive Neuroendocrine Neoplasms. Gastroenterology, 2016, 150, S302.	0.6	0
554	Comment traiter le moignon pancrÃ©atique aprÃ¨s duodÃ©nopancrÃ©atectomie cÃ©phalique. Journal De Chirurgie ViscÃ©rale, 2016, 153, 199-209.	0.0	0
555	Guideline for the Management of Pancreatic Neuroendocrine Tumor. , 2017, , 161-172.		0
556	Response to Malleo et al.. American Journal of Gastroenterology, 2017, 112, 1481-1482.	0.2	0
557	Results of Non-Operative Management for Intraductal Papillary Mucinous Neoplasms with High-Risk Stigmata or Worrisome Features: A Systematic Review and Meta-Analysis. Gastroenterology, 2017, 152, S681-S682.	0.6	0
558	Minimally Invasive Pancreatectomy plus Islet Autotransplantation for Benign Tumors of the Pancreatic Neck and Body. Updates in Surgery Series, 2018, , 187-194.	0.0	0

#	Article	IF	Citations
559	Unmet needs in the management of neuroendocrine tumours (NETs): A global survey of patients, patient advocates and healthcare professionals. Annals of Oncology, 2018, 29, viii475-viii476.	0.6	0
560	Focus on pancreatic cancer. Digestive and Liver Disease, 2018, 50, 1272-1273.	0.4	0
561	Prognostic role of hyponatremia in pancreatic cancer. Annals of Oncology, 2019, 30, iv7.	0.6	0
562	Double-stapled anastomosis versus mucosectomy and handsewn anastomosis in ileal pouch-anal anastomosis for ulcerative colitis or familial adenomatous polyposis. The Cochrane Library, 0, , .	1.5	0
563	Islet autotransplantation: Indication beyond chronic pancreatitis. , 2020, , 127-137.		0
564	Use of octreotide long acting repeatable (LAR) as second-line therapy in advanced neuroendocrine tumors in different clinical settings: an Italian Delphi survey. Expert Opinion on Pharmacotherapy, 2020, 21, 2317-2324.	0.9	0
565	New Surgical Strategies. , 2021, , 113-128.		0
566	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	2.4	0
567	Does chronic consumption of angiotensin-converting enzyme inhibitors affect survival after surgical resection of pancreatic ductal adenocarcinoma?. Digestive and Liver Disease, 2021, 53, 1065-1067.	0.4	0
568	Non Functional Pancreatic Neuroendocrine Tumors. , 2021, , 125-135.		0
569	Pancreatic Decompression in Chronic Pancreatitis. , 2004, , 474-478.		0
570	Cancer of the Exocrine Pancreas: Surgery and Multimodal Treatment. , 2009, , 89-100.		0
571	Clinical Aspect of Complications: Features and Prognoses. Medical Radiology, 2009, , 261-267.	0.0	0
572	Surgical and Interventional Perspective in Chronic Pancreatitis. Medical Radiology, 2009, , 383-390.	0.0	0
573	Pancreatic Endocrine Tumors. , 2009, , 163-175.		0
574	Cystic Pancreatic Tumors. , 2012, , 111-133.		0
575	Surgical Therapy. Updates in Surgery Series, 2013, , 109-116.	0.0	0
576	Prognostic factors in patients with pancreatic metastases from renal cell carcinoma (PM-RCC): Room for thinking about the role of surgery?. Journal of Clinical Oncology, 2014, 32, e15563-e15563.	0.8	0

#	Article	IF	Citations
577	Abstract 3455: Functional imaging tests vs. computed tomography scan: detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up. , 2015, , .		0
578	Functional imaging tests and CT scan: Detection of new metastases and clinical usefulness in digestive neuroendocrine neoplasms follow-up.. Journal of Clinical Oncology, 2016, 34, 219-219.	0.8	0
579	Nomogram to predict recurrence after curative resection of pancreatic neuroendocrine tumors.. Journal of Clinical Oncology, 2016, 34, e15654-e15654.	0.8	0
580	Abstract 3401: Impact of VEGF and VEGFR polymorphisms on neuroendocrine tumors of the gastro-entero-pancreatic system (GEPNETs) outcome. , 2016, , .		0
581	Outcome of Surgical Resection after Neoadjuvant Peptide Receptor Radionuclide Therapy (PRRT) for Pancreatic Neuroendocrine Neoplasms: a case-matched analysis. Endocrine Abstracts, 0, , .	0.0	0
582	Abstract 3519: TGF-Î² pathway alteration in pancreatic neuroendocrine tumors: characterization of a novel SMAD3 translocation. , 2017, , .		0
583	Therapy for Locoregional Disease: Pancreas. , 2018, , 235-254.		0
584	Pancreatic Neuroendocrine Tumours. , 2018, , 333-343.		0
585	Procedure terapeutiche. , 2008, , 67-81.		0
586	Preoperative risk stratification of postoperative pancreatic fistula: A risk-tree predictive model for pancreatoduodenectomy. Annals of Hepato-biliary-pancreatic Surgery, 2022, 26, S66-S66.	0.1	0